|
[1]
|
Kwan LY, Mahadevan U. Inflammatory bowel disease and pregnancy: an update[J]. Expert Rev Clin Immunol, 2010, 6: 643-657. doi: 10.1586/eci.10.35 |
|
[2]
|
Protic M, Seibold F, Schoepfer A, et al. The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients[J]. J Crohns Colitis, 2014, 8: 1427-1437. doi: 10.1016/j.crohns.2014.05.004 |
|
[3]
|
Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis[J]. Expert Rev Clin Pharmacol, 2012, 5: 113-123. doi: 10.1586/ecp.12.2 |
|
[4]
|
Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer[J]. Nat Rev Drug Discov, 2006, 5: 219-234. doi: 10.1038/nrd1984 |
|
[5]
|
Potter JM, Mcwhinney BC, Sampson L, et al. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population[J]. Ther Drug Monit, 2004, 26: 408-414. doi: 10.1097/00007691-200408000-00011 |
|
[6]
|
Moon W, Loftus EV Jr. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2016, 43: 863-883. doi: 10.1111/apt.13559 |
|
[7]
|
Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients[J]. Eur J Gastroenterol Hepatol, 2012, 24: 958-964. doi: 10.1097/MEG.0b013e3283545ae3 |
|
[8]
|
Stocco G, Cuzzoni E, De Iudicibus S, et al. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms[J]. World J Gastroenterol, 2015, 21: 3571-3578. doi: 10.3748/wjg.v21.i12.3571 |
|
[9]
|
Biancone L, Onali S, Petruzziello C, et al. Cancer and immunomodulators in inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2015, 21: 674-698. doi: 10.1097/MIB.0000000000000243 |
|
[10]
|
Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases[J]. Pharmacogenomics, 2011, 12: 1449-1463. doi: 10.2217/pgs.11.86 |
|
[11]
|
Jansen G, Van Der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis[J]. Arthritis Rheum, 2004, 50: 2130-2139. doi: 10.1002/art.20375 |
|
[12]
|
Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease[J]. Clin Pharmacokinet, 2001, 40: 723-751. doi: 10.2165/00003088-200140100-00003 |
|
[13]
|
Boyle B, Mackner L, Ross C, et al. A single-center experience with methotrexate after thiopurine therapy in pediatric Crohn disease[J]. J Pediatr Gastroenterol Nutr, 2010, 51: 714-717. doi: 10.1097/MPG.0b013e3181dd861a |
|
[14]
|
Bamba S, Tsujikawa T, Inatomi O, et al. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis[J]. J Gastroenterol Hepatol, 2010, 25: 494-498. doi: 10.1111/j.1440-1746.2009.06119.x |
|
[15]
|
Huttunen KM, Tani N, Juvonen RO, et al. Design, synthesis, and evaluation of novel cyclic phosphates of 5-aminosalicylic acid as cytochrome p450-activated prodrugs[J]. Mol Pharm, 2013, 10: 532-537. doi: 10.1021/mp300330v |
|
[16]
|
Hardy KW, Crocker JF, Mclellan H, et al. Paradoxical cyclosporine A requirements in pediatric renal transplants receiving high-dose steroids[J]. J Clin Pharmacol, 2005, 45: 161-167. doi: 10.1177/0091270004271403 |
|
[17]
|
Smith MA, Marinaki AM, Sanderson JD. Pharmacogenomics in the treatment of inflammatory bowel disease[J]. Pharmacogenomics, 2010, 11: 421-437. doi: 10.2217/pgs.10.4 |
|
[18]
|
Nakamura K, Matsuzawa N, Ohmori S, et al. Clinical evidence of pharmacokinetic changes in thalidomide therapy[J]. Drug Metab Pharmacokinet, 2013, 28: 38-43. doi: 10.2133/dmpk.DMPK-12-RV-089 |
|
[19]
|
Diamanti A, Capriati T, Papadatou B, et al. The clinical implications of thalidomide in inflammatory bowel diseases[J]. Expert Rev Clin Immunol, 2015, 11: 699-708. doi: 10.1586/1744666X.2015.1027687 |
|
[20]
|
Yarur AJ, Rubin DT. Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases[J]. Inflamm Bowel Dis, 2015, 21: 1709-1718. doi: 10.1097/MIB.0000000000000380 |
|
[21]
|
Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis[J]. Am J Gastroenterol, 2013, 108: 40-47. doi: 10.1038/ajg.2012.363 |
|
[22]
|
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease[J]. N Engl J Med, 2010, 362: 1383-1395. doi: 10.1056/NEJMoa0904492 |
作者投稿
专家审稿
编辑办公
邮件订阅
RSS
点击查看大图
下载:
